Publication:

Neonatal Fc Receptor: From Immunity to Therapeutics

Loading...
Thumbnail Image

Date

2010

Journal Title

Journal ISSN

Volume Title

Publisher

Springer US
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Kuo, Timothy T., Kristi Baker, Masaru Yoshida, Shuo-Wang Qiao, Victoria G. Aveson, Wayne I. Lencer, and Richard S. Blumberg. 2010. Neonatal Fc receptor: from immunity to therapeutics. Journal of Clinical Immunology 30(6): 777-789.

Abstract

The neonatal Fc receptor (FcRn), also known as the Brambell receptor and encoded by Fcgrt, is a MHC class I like molecule that functions to protect IgG and albumin from catabolism, mediates transport of IgG across epithelial cells, and is involved in antigen presentation by professional antigen presenting cells. Its function is evident in early life in the transport of IgG from mother to fetus and neonate for passive immunity and later in the development of adaptive immunity and other functions throughout life. The unique ability of this receptor to prolong the half-life of IgG and albumin has guided engineering of novel therapeutics. Here, we aim to summarize the basic understanding of FcRn biology, its functions in various organs, and the therapeutic design of antibody- and albumin-based therapeutics in light of their interactions with FcRn.

Description

Research Data

Keywords

FcRn, Fcgrt, Brambell, IgG, Fc, albumin, transcytosis, transport, recycling

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories